Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/1999
11/04/1999WO1999055304A1 Methods and compositions for stabilizing acetylcholine compositions
11/04/1999WO1999055302A1 Composition and method for treatment of aging skin
11/04/1999WO1999055298A1 Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
11/04/1999WO1999055296A1 Oral compositions
11/04/1999WO1999055294A1 Anhydrous aerosol hairspray compositions containing silicone grafted copolymers
11/04/1999WO1999055287A1 Topical anesthetic formulation
11/04/1999WO1999055285A2 Dilating and support apparatus with disease inhibitors and methods for use
11/04/1999WO1999055162A1 Method for the treatment of viral disease
11/04/1999WO1999055159A1 Serotonin potentiation by oleamide analogs
11/04/1999WO1999055158A1 S-rabeprazole compositions and methods
11/04/1999WO1999055157A1 R-rabeprazole compositions and methods
11/04/1999WO1999048894B1 Novel cephalotaxane derivatives and process for their preparation
11/04/1999WO1999047131A3 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
11/04/1999WO1999046381A3 Human fgf gene and gene expression products
11/04/1999WO1999046372A3 Ribozymes capable of inhibiting the expression of the ccr5 receptor
11/04/1999WO1999045926B1 Condensed heterocyclic compounds as anti-inflammatory and immunomodulatory agents
11/04/1999WO1999045909A3 Use of nitrone compounds for the inhibition of angiogenesis
11/04/1999WO1999044598A3 Methods for inhibiting βcell apoptosis
11/04/1999WO1999043355A3 Formulations containing oxaliplatin
11/04/1999WO1999042090A3 Treating cancer
11/04/1999WO1999041984A9 INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE)
11/04/1999WO1999040921A3 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
11/04/1999WO1999038858A8 Benzo[b]pyran derivatives useful as external agents for the skin
11/04/1999WO1999037788A9 Diagnosis and treatment of aur1 and/or aur2 related disorders
11/04/1999WO1999033981A3 Human signal peptide-containing proteins
11/04/1999WO1999031074A3 ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
11/04/1999WO1999019481A3 Mammalian genes involved in viral infection and tumor suppression
11/04/1999WO1998027073A8 Asymmetric synthesis of benzoxazinones
11/04/1999DE19907764A1 Preparation of acid-resistant pancreatin granulates
11/04/1999DE19819548A1 Biphenylderivate Biphenyl
11/04/1999DE19819023A1 Thienopyrimidine Thienopyrimidines
11/04/1999DE19818964A1 New hydroxy-indole derivatives useful in treatment of degenerative joint disease, viral and parasitic infections, bronchial, dermatological, neurodegenerative and prostate disorders, etc.
11/04/1999DE19812204A1 Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung The use of extracts from Cimicifuga racemosa and Belamcanda sinensis estrogenartiges organ-selective drugs without a uterotrophic effect
11/04/1999CA2330934A1 Composition containing polyacrylate, polyterpene, nitroglycerine and possibly polyvinyl acetate
11/04/1999CA2330685A1 Process for making 1,3-disubstituted-4-oxocyclic ureas
11/04/1999CA2330644A1 Solution containing nicotine
11/04/1999CA2330577A1 Serotonergic agents
11/04/1999CA2330576A1 Substituted benzazocines as nicotine-binding inhibitors
11/04/1999CA2330564A1 Quinolones used as mrs inhibitors and bactericides
11/04/1999CA2330563A1 Therapeutic anti-cold agent containing isomalt as an active ingredient
11/04/1999CA2330475A1 1-¬(1-substituted-4-piperidinyl)methyl|-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
11/04/1999CA2330458A1 Methods of identifying and using hla binding compounds as hla-agonists and antagonists
11/04/1999CA2330452A1 Antipsychotic indolyl derivatives
11/04/1999CA2330437A1 Indolyl derivatives as serotonergic agents
11/04/1999CA2330436A1 Indolyl derivatives as serotonergic agents
11/04/1999CA2330428A1 Treatment of mastitis
11/04/1999CA2330391A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999CA2330387A1 Treatment of papilloma virus infection using a mycobacterium
11/04/1999CA2330324A1 S-rabeprazole compositions and methods
11/04/1999CA2330304A1 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
11/04/1999CA2330139A1 R-rabeprazole compositions and methods
11/04/1999CA2330111A1 Phosphonic acid diester derivatives and their use in lowering blood glucose level and treating diabetes
11/04/1999CA2330055A1 Paroxetine ascorbate
11/04/1999CA2330033A1 Method of treating endotoxemia
11/04/1999CA2329982A1 Membrane-permeant phosphoinositides
11/04/1999CA2329929A1 Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
11/04/1999CA2329921A1 Imidazo pyridine derivatives which inhibit gastric acid secretion
11/04/1999CA2329913A1 Paroxetine 10-camphorsulfonate for treatment of cns disorders
11/04/1999CA2329864A1 Fire-resistant non-explosive solid mixtures containing nitroglycerine and water-free lactose
11/04/1999CA2329821A1 Ccr-3 receptor antagonists
11/04/1999CA2329777A1 Ccr-3 receptor antagonists
11/04/1999CA2329762A1 Pharmaceutical imidazole combination for locally treating vulvovaginitis and vaginosis
11/04/1999CA2329709A1 Compounds and methods for treating mitochondria-associated diseases
11/04/1999CA2329434A1 Pharmaceutically available protoberberine salts derivatives, and protoberberine derivatives and salts thereof
11/04/1999CA2329328A1 Use of nmda antagonists for treatment of irritable bowel syndrome
11/04/1999CA2329235A1 Anhydrous aerosol hairspray compositions containing silicone grafted copolymers
11/04/1999CA2328970A1 Pellets having a core coated with a lipid lowering agent and a polymer
11/04/1999CA2328929A1 Serotonin potentiation by oleamide analogs
11/04/1999CA2328778A1 Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
11/04/1999CA2328165A1 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
11/04/1999CA2328111A1 Compositions and methods for extending the action of clostridial neurotoxin
11/04/1999CA2327363A1 Process for the preparation of methyl(2s)-2-¬(3r)-3-(n-¬tert-butyloxycarbonyl|-amino)-2-oxopyrrolidin-1-yl|propionate
11/04/1999CA2326825A1 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999CA2326824A1 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999CA2326695A1 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection
11/04/1999CA2326601A1 Ese genes and proteins
11/04/1999CA2326375A1 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
11/04/1999CA2325736A1 Guanidine derivatives
11/03/1999EP0953641A2 Polynucleotide molecules encoding neospora proteins
11/03/1999EP0953637A2 Acetylcholine receptor
11/03/1999EP0953636A2 Cytokine signal regulators
11/03/1999EP0953630A1 Transesterification products of corn oil and glycerol and their use in pharmaceutical compositions
11/03/1999EP0953570A1 Fluorinated cephalosporin antibiotics and their use for the treatment of mastitis
11/03/1999EP0953568A1 Benzothiophene pharmaceutical compounds
11/03/1999EP0953567A2 Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
11/03/1999EP0953353A1 Use of procyanidolic oligomers or anthocyanosides as anti-urease agents
11/03/1999EP0953350A1 Extended release formulation of diltiazem hydrochloride
11/03/1999EP0953349A1 Compositions comprising nitroglycerin and anhydrous lactose
11/03/1999EP0953347A2 Use of graft polymers containing polyalkyleneoxides as solubilizers
11/03/1999EP0953346A1 Use of at least a hydroxystilbebe in a skin fortifying composition
11/03/1999EP0953345A1 Use of at least a hydroxystilbene as an agent for decreasing micro-organism adhesion
11/03/1999EP0953344A1 Use of at least one hydroxystilbene in a composition to stimulate desquamation of the skin and compositions containing it
11/03/1999EP0953338A1 Packaging device for a product
11/03/1999EP0953294A2 Use of 3,6-Dimethyl-2-(3H)-benzofuranone as a flavouring agent and new process for its preparation
11/03/1999EP0953053A2 Viral particles which are masked or unmasked with respect to a cell receptor
11/03/1999EP0952975A1 Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
11/03/1999EP0952974A1 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
11/03/1999EP0952855A1 Use of hyaluronan in gene therapy
11/03/1999EP0952853A2 Conjugate comprising an active agent, a polypeptide and a polyether
11/03/1999EP0952844A1 USE OF PROTEIN S-100b IN MEDICINES AND MEDICINES CONTAINING THE PROTEIN S-100b
1 ... 6418 6419 6420 6421 6422 6423 6424 6425 6426 6427 6428 6429 6430 6431 6432 6433 6434 6435 6436 6437 6438 ... 7860